CSI markets minimally invasive devices to remove vascular plaques and has a full pipeline of complementary vascular intervention technologies. Abbott expects CSI’s products to complement its existing coronary intervention business and expand its presence in the peripheral market.

During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.

The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.

TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.